Key clinical point: Galcanezumab, a calcitonin gene-related peptide monoclonal antibody targeting the peripheral nervous system, led to early improvement in the severity of symptoms associated with central sensitization in patients with migraine.
Major findings: The Central Sensitization Inventory score significantly decreased from 36.0 at baseline to 29.7 at 3 months and 29.3 at 6 months after galcanezumab treatment ( P < .001). The Allodynia Symptom Checklist score decreased from 5.55 at baseline to 4.09 at 3 months ( P < .01) and 4.26 at 6 months ( P < .01) with galcanezumab treatment.
Study details: This prospective real-world study included 86 patients with migraine (age, 20-65 years) who were treated with galcanezumab (240 mg administered initially, followed by 120 mg monthly) for 6 months.
Disclosure: This study was funded by the Ministry of Health, Labor and Welfare, Japan. Several authors reported having ties with various sources.
Source: Danno D, Imai N, Kitamura S, Ishizaki K, Kikui S, Takeshima T. Efficacy of galcanezumab in migraine central sensitization. Sci Rep. 2024; 14:21824. Source